<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02478229</url>
  </required_header>
  <id_info>
    <org_study_id>15-8883-A</org_study_id>
    <nct_id>NCT02478229</nct_id>
  </id_info>
  <brief_title>Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)</brief_title>
  <official_title>Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single centre, single arm, open-label, proof of concept study enrolling 20
      adult primary liver transplant recipients with genotype 1 HCV infection. Subjects will
      receive Sofosbuvir (SOF) and Ledipasvir (LDV) starting at time of liver transplantation (OLT)
      and continues for 12 weeks. Subjects will be receive 24 week post-treatment follow up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatitis C viral infection (HCV) leading to end-stage liver disease is the leading
      indication for liver transplant worldwide. HCV recurrence following liver transplantation is
      universal, associated with 100-fold increase in viremia levels, and runs at an accelerated
      course, leading to graft cirrhosis in up to 30% of patients within 5 years. Successful
      eradication of HCV post transplant normalizes the long term survival of HCV positive liver
      transplant recipients. This study aims to treat HCV infection starting at the time of
      transplant. The study is a single centre, single arm, open-label,proof of concept study
      enrolling 20 adult primary liver transplant recipients with genotype 1 HCV infection.
      Subjects will receive Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose
      combination (FDC) tablet starting at time of liver transplantation (OLT) and continues for 12
      weeks. Subjects will receive 24 week post-treatment follow up. The study will investigate if
      the patient has achieved sustained virological response (SVR) 12 weeks after cessation of
      treatment (SVR12). Furthermore, safety and efficacy of this treatment regimen beginning at
      the time of transplant will be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    difficulty recruiting patients
  </why_stopped>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virological Response (SVR12)</measure>
    <time_frame>12 weeks after cessation of treatment</time_frame>
    <description>Defined as HCV RNA in serum below lower limit of quantification (LLOQ)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Virological Response (SVR24)</measure>
    <time_frame>24 weeks after cessation of treatment</time_frame>
    <description>Defined as HCV RNA in serum below lower limit of quantification (LLOQ)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Virological Relapse</measure>
    <time_frame>12 weeks after cessation of treatment or 24 weeks after cessation of treatment (becoming quantifiable again at 12 (relapse 12) or 24 (relapse 24) weeks after cessation of treatment, respectively)</time_frame>
    <description>Defined as HCV RNA in serum below lower limit of quantification (LLOQ)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Hepatitis C Viral Infection</condition>
  <arm_group>
    <arm_group_label>SOF and LDV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm: All participants will be started on Sofosbuvir (SOF) 400 mg and Ledipasvir (LDV) 90 mg as a fixed dose combination (FDC) tablet p.o. once daily with or without food starting at the time of liver transplantation (OLT), i.e. first doses given immediately prior to OLT, and continuing for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir (SOF) and Ledipasvir (LDV)</intervention_name>
    <arm_group_label>SOF and LDV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipient of a first (primary) live or deceased (after brain or cardiac death) donor
             liver transplant

          -  Willing and able to provide written informed consent

          -  Male or Female, age 18-70 years old

          -  Medical MELD score â‰¤30 at time of transplant (calculated based on serum bilirubin,
             creatinine and INR, i.e. not taking exception points into account)

          -  Quantifiable HCV RNA at time of listing or transplant evaluation

          -  HCV genotype 1a or 1b infection

          -  Female patients must have a negative pregnancy test at enrolment

        Exclusion Criteria:

          -  Liver re-transplantation

          -  Recipients of multiple solid organ transplants

          -  Estimated GFR &lt;30ml/min at time of transplant

          -  Participants transplanted for fulminant hepatic failure

          -  Participants co-infected with HBV or HIV

          -  Previous treatment with a Sofosbuvir or Ledipasvir containing regimen

          -  Participation in an interventional clinical trial within 1 month prior to enrolment

          -  Known allergies or hypersensitivity to Sofosbuvir or Ledipasvir

          -  Pregnancy and/or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eberhard Renner, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Health Network, Toronto</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P; ION-2 Investigators. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17;370(16):1483-93. doi: 10.1056/NEJMoa1316366. Epub 2014 Apr 11.</citation>
    <PMID>24725238</PMID>
  </reference>
  <reference>
    <citation>Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR; PHOENIX Study Group. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl. 2011 May;17(5):528-38. doi: 10.1002/lt.22271.</citation>
    <PMID>21506241</PMID>
  </reference>
  <reference>
    <citation>Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013 Jan 3;368(1):34-44. doi: 10.1056/NEJMoa1208953.</citation>
    <PMID>23281974</PMID>
  </reference>
  <reference>
    <citation>Osinusi A, Meissner EG, Lee YJ, Bon D, Heytens L, Nelson A, Sneller M, Kohli A, Barrett L, Proschan M, Herrmann E, Shivakumar B, Gu W, Kwan R, Teferi G, Talwani R, Silk R, Kotb C, Wroblewski S, Fishbein D, Dewar R, Highbarger H, Zhang X, Kleiner D, Wood BJ, Chavez J, Symonds WT, Subramanian M, McHutchison J, Polis MA, Fauci AS, Masur H, Kottilil S. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. JAMA. 2013 Aug 28;310(8):804-11. doi: 10.1001/jama.2013.109309. Erratum in: JAMA. 2013 Nov 13;310(18):1987. Dosage error in article text.</citation>
    <PMID>23982366</PMID>
  </reference>
  <reference>
    <citation>Selzner N, Renner EL, Selzner M, Adeyi O, Kashfi A, Therapondos G, Girgrah N, Herath C, Levy GA, Lilly L. Antiviral treatment of recurrent hepatitis C after liver transplantation: predictors of response and long-term outcome. Transplantation. 2009 Nov 27;88(10):1214-21. doi: 10.1097/TP.0b013e3181bd783c.</citation>
    <PMID>19935376</PMID>
  </reference>
  <reference>
    <citation>Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM; AI444040 Study Group. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014 Jan 16;370(3):211-21. doi: 10.1056/NEJMoa1306218. Erratum in: N Engl J Med. 2014 Apr 10;370(15):1469.</citation>
    <PMID>24428467</PMID>
  </reference>
  <reference>
    <citation>Tanaka T, Therapondos G, Selzner N, Renner EL, Lilly LB. Serum aspartate aminotransferase levels and previous histopathological findings enable reduction of protocol liver biopsies after liver transplantation for hepatitis C. Can J Gastroenterol. 2013 Mar;27(3):131-6.</citation>
    <PMID>23516677</PMID>
  </reference>
  <reference>
    <citation>Tanaka T, Benmousa A, Marquez M, Therapondos G, Renner EL, Lilly LB. The long-term efficacy of nucleos(t)ide analog plus a year of low-dose HBIG to prevent HBV recurrence post-liver transplantation. Clin Transplant. 2012 Sep-Oct;26(5):E561-9. doi: 10.1111/ctr.12022.</citation>
    <PMID>23061767</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2015</study_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver transplant</keyword>
  <keyword>Genotype 1 HCV infection</keyword>
  <keyword>Sofosbuvir (SOF)/ Ledipasvir (LDV)</keyword>
  <keyword>Sustained virological response (SVR12 )</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

